Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion

The aim of this study was to investigate the performance of three new solid dispersion formulations of itraconazole in human volunteers in comparison with Sporanox((R)), the marketed form. Solid dispersions made up of itraconazole (40%, w/w) and HPMC 2910, Eudragit E100 or a mixture of Eudragit E100-PVPVA64 were manufactured by hot-stage extrusion and filled in gelatin capsules. The formulations were tested in eight human volunteers in a double blind, single dose, and cross-over study. Concentrations of the drug and its metabolite hydroxyitraconazole in the plasma were determined using HPLC. The in vivo performance was evaluated by comparing the mean area under the plasma concentration-time curves (AUC), the mean maximum plasma concentration (C-max), and the mean time to reach C-max (T-max). The mean bioavailability of itraconazole was comparable after administration of the HPMC solid dispersion, compared to Sporanoxo((R)), while it was lower after administration of the Eudragit E100 or Eudragit EI100-PVPVA64 dispersions. Due to high variability, a significant decrease in AUC and C-max was only observed for the Eudragit E100-PVPVA formulation. Although the solid dispersions showed different in vitro dissolution behaviour, T-max values were comparable. The same observations with respect to AUC, C-max and T-max could be made for hydroxyitraconazole. The present results indicate that hot-stage extrusion can be considered as a valuable alternative for manufacturing solid dispersions of itraconazole. (C) 2004 Elsevier B.V. All rights reserved.